Operations and Support
Schedules
TAFS: 070-0540 2021/2023 - Operations and Support
| Line # | Split | Description | Iteration 1 Previously Approved Amount | Iteration 2 Current OMB Action Amount | Footnotes |
|---|---|---|---|---|---|
| 1000 | A | Unob Bal: Brought forward, Oct 1 | Line added— | +$1,559,690 $1,559,690 | |
| 1000 | E | Unob Bal: Brought forward, Oct 1 | $1,737,432 | -$1,737,432 Line removed— | |
| 1021 | Unob Bal: Recov of prior year unpaid obligations | Line added— | +$48,497 $48,497 | ||
| 1061 | Unob Bal: Antic recov of prior year unpd/pd obl | $500,000 | -$48,497 $451,503 | ||
| 1700 | BA: Disc: Spending auth: Collected | Line added— | +$192,585 $192,585 | ||
| 1701 | BA: Disc: Spending auth: Chng uncoll pymts Fed src | Line added— | +$1,370,068 $1,370,068 | ||
| 1740 | BA: Disc: Spending auth:Antic colls, reimbs, other | $3,500,000 | -$1,562,653 $1,937,347 | ||
| 1920 | Total budgetary resources avail (disc. and mand.) | $5,737,432 | -$177,742 $5,559,690 | ||
| 6001 | Category A -- 1st quarter | $3,750,000 | $3,750,000 | ||
| 6002 | Category A -- 2nd quarter | $1,287,432 | $1,287,432 | ||
| 6003 | Category A -- 3rd quarter | $500,000 | -$177,742 $322,258 | ||
| 6004 | Category A -- 4th quarter | $200,000 | $200,000 | ||
| 6190 | Total budgetary resources available | $5,737,432 | -$177,742 $5,559,690 | ||
Footnotes
Footnotes provide further information about, or establish further legal requirements related to the use of, the funds in a given line or set of lines in an apportionment. If footnotes appear on lines 1920 or 6190, they apply to all the lines in the 1xxx and 6xxx sections, respectively. The following are all the footnotes associated with this file.
No footnotes available.
The following are all of the footnotes associated with the previous iteration of this file. Note that previous iterations of accounts in this file may come from multiple previous files.
No footnotes available.
Notes about this page
- † Links to public laws are automatically generated and are not guaranteed to be accurate.